Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ZJG
|
|||
| Former ID |
DCL000197
|
|||
| Drug Name |
PI-88
|
|||
| Synonyms |
CHEMBL603733
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1] | |
| Prostate cancer [ICD-11: 2C82.0] | Phase 2 | [1] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Progen Industries
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H35Na15O77PS16-3
|
|||
| Canonical SMILES |
C(C1C(C(C(C(O1)OC2C(C(OC(C2OS(=O)(=O)[O-])OC3C(C(OC(C3OS(=O)(=O)[O-])OC4C(C(OC(C4OS(=O)(=O)[O-])OC5C(C(C(OC5OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
|
|||
| InChI |
1S/C30H53O77PS16.15Na/c31-108(32,33)82-1-6-14(99-116(55,56)57)20(102-119(64,65)66)25(106-123(76,77)78)29(87-6)94-17-12(97-114(49,50)51)8(3-84-110(37,38)39)89-27(23(17)104-121(70,71)72)92-16-11(96-113(46,47)48)7(2-83-109(34,35)36)88-26(22(16)103-120(67,68)69)93-18-13(98-115(52,53)54)9(4-85-111(40,41)42)90-28(24(18)105-122(73,74)75)95-21-19(101-118(61,62)63)15(100-117(58,59)60)10(5-86-112(43,44)45)91-30(21)107-124(79,80)81;;;;;;;;;;;;;;;/h6-30H,1-5H2,(H2,31,32,33)(H,34,35,36)(H,37,38,39)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81);;;;;;;;;;;;;;;/q;15*+1/p-18/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-;;;;;;;;;;;;;;;/m1.............../s1
|
|||
| InChIKey |
FIYNUMVQYZZZCH-JSZMYKOGSA-A
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 3 (FLT-4) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Pathway Interaction Database | VEGF and VEGFR signaling network | |||
| VEGFR3 signaling in lymphatic endothelium | ||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | |||
| WikiPathways | Signaling by VEGF | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 2 | Company report (Medigen) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.